Condition: Coronary Artery Disease · Coronary Microvascular Dysfunction · Overweight or Obesity · Sponsor: Tina Vilsbøll
The objective of this study is to investigate, as a proof-of-principle, long-term (52 weeks) effects of tirzepatide once-weekly vs. placebo on changes in coronary plaque composition and progression (assessed by NIRS), plaque burden (assessed by IVUS) and microvascular function (assessed by invasively measured CFR) in overweight and obese individuals with stable coronary artery disease (CAD). In addition, the objective of a baseline cross-sectional sub-study is to explore potential metabolic and cardiovascular (CV) predictors for high arteriosclerotic plaque burden in overweight and obese individuals and to establish a cohort for future research projects.
This description comes directly from the study's public registry record.
Daniel Raaschou-Oddershede, MD · +4520157448 · daniel.raaschou-oddershede@regionh.dk
Christine Rode Schwarz, MD, PhD · christine.rode.schwarz@regionh.dk
Always discuss trial participation with your own doctor first.
| Rigshospitalet | Copenhagen, Denmark | Not Yet Recruiting |
| Gentofte Hospital | Gentofte Municipality, Denmark | Recruiting |
| Steno Diabetes Center Copenhagen | Herlev, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06606821